Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Nicardipine hydrochloride controlled-release preparation

A technology of nicardipine hydrochloride and nicardipine hydrochloride, which is applied in the field of medicine, can solve the problems of frequent doses, troubles for patients, and short intervals, etc., and achieve the effects of reducing the number of doses, improving compliance, and lasting and stable blood drug concentration

Inactive Publication Date: 2003-11-12
SHENYANG PHARMA UNIVERSITY
View PDF0 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0002] There are many types of drugs for the treatment of hypertension and coronary heart disease, but in order to maintain a good curative effect and stabilize the blood pressure of patients, it is necessary to take the drugs on time. in trouble

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nicardipine hydrochloride controlled-release preparation
  • Nicardipine hydrochloride controlled-release preparation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] Using film coating technology, nicardipine hydrochloride is made into double-layer osmotic pump controlled-release tablets, and laser drilling is performed on one side to achieve the purpose of controlled release. Present embodiment 1 (composition is calculated by tablet core weight percentage) contains following composition:

[0016] Nicardipine Hydrochloride 14.2%

[0017] Polyoxyethylene N80 31.7%

[0018] Poloxamer 10.7%

[0019] Appropriate amount of talcum powder

[0020] Magnesium Stearate Appropriate amount

[0021] 10% povidone K30 ethanol solution appropriate amount

[0022] Boost layer:

[0023] Polyoxyethylene WSR303 24.5%

[0024] Hypromellose 1.2%

[0025] Sodium Chloride 3.6%

[0026] Povidone 10.7%

[0027] Iron oxide red amount

[0028] Magnesium Stearate Appropriate amount

[0029] 10% povidone K30 ethanol solution appropriate amount

[0030] Coating layer:

[0031] Composition of semi-permeable membrane coating solution (for every 1000 ta...

Embodiment 2

[0043] Adopt film coating technology with example 1. Present embodiment 2 (composition is calculated by tablet core weight percentage) contains following composition:

[0044] Drug layer:

[0045] Nicardipine Hydrochloride 14.2%

[0046] Polyoxyethylene N10 31.7%

[0047] Poloxamer 10.7%

[0048] Appropriate amount of talcum powder

[0049] Magnesium Stearate Appropriate amount

[0050] 10% povidone K30 ethanol solution appropriate amount

[0051] Boost layer:

[0052] Polyoxyethylene WSR303 24.5%

[0053] Hypromellose 1.2%

[0054] Sodium Chloride 3.6%

[0055] Povidone 10.7%

[0056] Iron oxide red amount

[0057] Magnesium Stearate Appropriate amount

[0058]10% povidone K30 ethanol solution appropriate amount

[0059] Coating layer:

[0060] Composition of semi-permeable membrane coating solution (for every 1000 tablets)

[0061] Cellulose acetate 25g

[0062] Polyethylene glycol (PEG4000) 0.85g

[0063] Acetone: water 805ml

[0064] Composition of moistu...

Embodiment 3

[0072] Adopt film coating technology with example 1. Present embodiment 3 (composition is calculated by tablet core weight percentage) contains following composition:

[0073] Drug layer:

[0074] Nicardipine Hydrochloride 14.2%

[0075] Hypromellose 31.7%

[0076] Poloxamer 10.7%

[0077] Appropriate amount of talcum powder

[0078] Magnesium Stearate Appropriate amount

[0079] 10% povidone K30 ethanol solution appropriate amount

[0080] Boost layer:

[0081] Polyoxyethylene WSR303 24.5%

[0082] Hypromellose 1.2%

[0083] Sodium Chloride 3.6%

[0084] Povidone 10.7%

[0085] Iron oxide red amount

[0086] Magnesium Stearate Appropriate amount

[0087] 10% povidone K30 ethanol solution appropriate amount

[0088] Coating layer:

[0089] Composition of semi-permeable membrane coating solution (for every 1000 tablets)

[0090] Cellulose acetate 25g

[0091] Polyethylene glycol (PEG4000) 0.85g

[0092] Acetone: water 805ml

[0093] Composition of moisture-pro...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a hydrochloric nicardipine medicinal preparation control-released under the gastrointestinal tract environment. The preparation contains the polymer that can be accepted by the hydrochloric nicardipine and the pharmacy. According to wt%, the hydrochloric nicardipine 10-30%, the control-releasing assorted material 35-60%, and the rest of assorted material. The control-releasing assorted material is polyoxyethylene and / or hydroxypropyl methyl cellulose and / or sodium alginate or chloride and / or lactose and / or mannite and / or sucrose and / or calcium biphosphate and / or low-substituted hydroxypropyl cellulose and / or avicel and / or cross-linked sodium cellulose glycollate and / or cross-linked polyvinylpyrrolidone and / or cellulose acetate.

Description

Technical field: [0001] The invention relates to the technical field of medicine, specifically, it is a nicardipine hydrochloride controlled-release preparation for mainly treating essential hypertension, angina pectoris of coronary heart disease, hypertrophic cardiomyopathy and preventing atherosclerosis. Background technique: [0002] There are many types of drugs for the treatment of hypertension and coronary heart disease, but in order to maintain a good curative effect and stabilize the blood pressure of patients, it is necessary to take the drugs on time. trouble. Invention content: [0003] The object of the present invention is to provide a kind of nicardipine hydrochloride controlled-release preparation, it can reduce the number of times of taking medicine, can maintain the nicardipine hydrochloride controlled-release preparation of stable effective blood drug concentration within 24 hours. Its advantages can reduce the number of times of taking medicine, and the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/22A61K31/4422A61P9/10A61P9/12
Inventor 潘卫三郑启兰刘宏飞
Owner SHENYANG PHARMA UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com